Annovis to Attend the AAIC 2025 with Four Poster Presentations
Annovis Bio (NYSE:ANVS) announced its participation in the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada. The company will present four scientific posters focused on their lead drug candidate, buntanetap, for Alzheimer's disease treatment.
The presentations will cover the Phase III study design for early Alzheimer's patients, details of their 6-month and 18-month pivotal clinical trial, and pharmacokinetic characterization studies of buntanetap in both animals and humans. Senior management team members, including SVP of R&D and other key scientists, will present the research findings at this premier global conference for dementia science.
Annovis Bio (NYSE:ANVS) ha annunciato la sua partecipazione alla Alzheimer's Association International Conference (AAIC), che si terrà dal 27 al 31 luglio 2025 a Toronto, Canada. L'azienda presenterà quattro poster scientifici incentrati sul suo principale candidato farmaco, buntanetap, per il trattamento della malattia di Alzheimer.
Le presentazioni riguarderanno il progetto dello studio di Fase III per pazienti con Alzheimer in fase iniziale, i dettagli del loro trial clinico fondamentale di 6 e 18 mesi e gli studi di caratterizzazione farmacocinetica di buntanetap sia negli animali che negli esseri umani. I membri del team di senior management, inclusi il SVP di R&S e altri scienziati chiave, presenteranno i risultati della ricerca a questa conferenza globale di riferimento per la scienza della demenza.
Annovis Bio (NYSE:ANVS) anunció su participación en la Conferencia Internacional de la Asociación de Alzheimer (AAIC), que se llevará a cabo del 27 al 31 de julio de 2025 en Toronto, Canadá. La compañía presentará cuatro pósters científicos centrados en su principal candidato a fármaco, buntanetap, para el tratamiento de la enfermedad de Alzheimer.
Las presentaciones cubrirán el diseño del estudio de Fase III para pacientes con Alzheimer temprano, detalles de su ensayo clínico pivotal de 6 y 18 meses, y estudios de caracterización farmacocinética de buntanetap en animales y humanos. Miembros del equipo directivo senior, incluyendo el vicepresidente senior de I+D y otros científicos clave, presentarán los hallazgos de la investigación en esta conferencia global de referencia en ciencia de la demencia.
Annovis Bio (NYSE:ANVS)는 2025년 7월 27일부터 31일까지 캐나다 토론토에서 열리는 알츠하이머 협회 국제 학술대회(AAIC)에 참가한다고 발표했습니다. 회사는 알츠하이머병 치료를 위한 주요 약물 후보인 buntanetap에 관한 네 편의 과학 포스터를 발표할 예정입니다.
발표 내용은 초기 알츠하이머 환자를 위한 3상 임상시험 설계, 6개월 및 18개월 중추 임상시험의 세부사항, 그리고 동물과 인간을 대상으로 한 buntanetap의 약동학 특성화 연구를 포함합니다. 연구개발 부사장 및 주요 과학자들을 포함한 고위 경영진이 치매 과학 분야의 세계적 권위 학술대회에서 연구 결과를 발표할 것입니다.
Annovis Bio (NYSE:ANVS) a annoncé sa participation à la Conférence internationale de l'Association Alzheimer (AAIC) qui se tiendra du 27 au 31 juillet 2025 à Toronto, Canada. La société présentera quatre posters scientifiques axés sur son principal candidat-médicament, buntanetap, pour le traitement de la maladie d'Alzheimer.
Les présentations porteront sur le design de l'étude de phase III chez les patients atteints d'Alzheimer précoce, les détails de leur essai clinique pivot de 6 et 18 mois, ainsi que des études de caractérisation pharmacocinétique de buntanetap chez l'animal et l'humain. Des membres de la haute direction, dont le vice-président senior de la R&D et d'autres scientifiques clés, présenteront les résultats de la recherche lors de cette conférence mondiale de référence en sciences de la démence.
Annovis Bio (NYSE:ANVS) gab bekannt, dass es an der Alzheimer's Association International Conference (AAIC) vom 27. bis 31. Juli 2025 in Toronto, Kanada, teilnehmen wird. Das Unternehmen wird vier wissenschaftliche Poster vorstellen, die sich auf ihren führenden Arzneimittelkandidaten buntanetap zur Behandlung der Alzheimer-Krankheit konzentrieren.
Die Präsentationen umfassen das Design der Phase-III-Studie für Patienten mit frühem Alzheimer, Details zu ihrer entscheidenden klinischen Studie über 6 und 18 Monate sowie pharmakokinetische Charakterisierungsstudien von buntanetap sowohl an Tieren als auch an Menschen. Mitglieder des Senior-Management-Teams, darunter der SVP für Forschung und Entwicklung sowie weitere wichtige Wissenschaftler, werden die Forschungsergebnisse auf dieser weltweit führenden Konferenz für Demenzforschung vorstellen.
- None.
- None.
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s clinical program and pharmacokinetic characterization of its lead drug candidate, buntanetap.
Presentation details:
- Poster #1: Design of Phase III study testing buntanetap efficacy in early Alzheimer’s patients based on the insights from previous studies.
Presenter: Cheng Fang, Ph.D., Senior Vice President, Research & Development.
- Poster #2: A dual 6-month & 18-month prospective, randomized, placebo-controlled, double-blind, pivotal clinical trial investigating efficacy and safety of buntanetap in early Alzheimer's patients.
Presenter: Sarah MacCallum, Director of Clinical Operations.
- Poster #3: Advancing buntanetap: comparative pharmacokinetic characterization of the original semi-crystalline with the novel crystalline form in animals and humans.
Presenter: Alexander Morin, Ph.D., Director of Strategic Communications.
- Poster #4: Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases.
Presenter: Matthew Peterson, Ph.D., Senior Clinical Scientist.
The AAIC 2025 is the world’s largest meeting dedicated to advancing the science and clinical practice of dementia. Each year, the conference brings together researchers, clinicians, and professionals from around the globe to share cutting-edge discoveries and clinical insights aimed at improving the diagnosis, treatment, and care of individuals affected by AD and other dementias.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
When and where will Annovis Bio (ANVS) present at AAIC 2025?
What will Annovis Bio (ANVS) present at AAIC 2025?
Who are the presenters from Annovis Bio (ANVS) at AAIC 2025?
What is the focus of Annovis Bio's (ANVS) Phase III study presented at AAIC 2025?
